Table 1. The clinical and histopathologic features of the subjects.
| Variables | Total | GR | I-GR | I-LMDF | LMDF | Others | |
|---|---|---|---|---|---|---|---|
| No. | 62 | 18 | 10 | 8 | 13 | 13 | |
| Age (mean ± SD) | 47.3±13.8 | 51.7±11.9 | 46.9±14.7 | 47.9±15.6 | 44.4±13.0 | 44.2±15.4 | |
| Sex (male:female) | 1:1.3 | 1:3.5 | 1:0.6 | 1:3.0 | 1:0.8 | 1:0.8 | |
| Vascular symptom | 53.2% | 77.7%* | 60.0% | 50.0% | 23.0% | 46.1% | |
| Aggravation on external stimuli | 40.3% | 61.1%* | 40.0% | 37.5% | 15.3% | 38.4% | |
| Lesion distribution | |||||||
| Eyelid | 45.1% | 27.7% | 50.0% | 75.0%* | 84.6%* | 7.7% | |
| Forehead | 77.4% | 83.3% | 70.0% | 75.0% | 92.3% | 61.5% | |
| Nose | 70.9% | 83.3% | 90.0% | 50.0% | 100.0% | 23.0% | |
| Perioral area | 64.5% | 61.1% | 50.0% | 87.6% | 76.9% | 53.9% | |
| Cheek | 85.4% | 100.0% | 80.0% | 62.5% | 92.3% | 76.9% | |
| Chin | 72.5% | 88.9% | 50.0% | 75.0% | 69.2% | 69.2% | |
| Extrafacial area | 8.1% | 11.1% | 0.0% | 12.5% | 7.7% | 8.3% | |
| Lesion appearance | |||||||
| Background erythema | 59.6% | 88.9%* | 60.0% | 37.5% | 46.2% | 46.2% | |
| Telangiectasia | 58.0% | 93.3%* | 90.0%* | 50.0% | 30.8% | 30.8% | |
| Deep-seated papule | 32.2% | 22.2% | 10.0% | 50.0% | 76.9%* | 7.7% | |
| Pustule | 16.1% | 33.3% | 0.0% | 0.0% | 23.0% | 7.7% | |
| Histopathology | |||||||
| Caseation necrosis | 17.7% | 5.6% | 10.0% | 37.5%* | 38.5%* | 7.7% | |
| Epithelioid granuloma | 59.6% | 55.6% | 60.0% | 75.0% | 84.6% | 30.8% | |
| Capillary dilatation | 83.8% | 88.9% | 90.0% | 87.5% | 84.6% | 69.2% | |
| Solar elastosis | 53.2% | 61.1% | 70.0% | 50.0% | 46.2% | 38.5% | |
| Demodex folliculorum | 14.5% | 27.8% | 10.0% | 12.5% | 7.7% | 7.7% | |
GR: granulomatous rosacea, I-GR: indeterminate granulomatous rosacea, I-LMDF: indeterminate lupus miliaris disseminatus faciei, LMDF: lupus miliaris disseminatus faciei, SD: standard deviation.
*p<0.05.